Integra Lifesciences Holdings (IART) Change in Accured Expenses (2009 - 2026)

Integra Lifesciences Holdings' Change in Accured Expenses history runs 18 years deep, the most recent figure standing at -$19.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 6.59% year-over-year to -$19.2 million; the TTM figure through Mar 2026 stood at $25.5 million (up 1844.4% YoY), while the FY2025 annual figure was $26.7 million, up 1099.4% from the prior year.
• Change in Accured Expenses came in at -$19.2 million for Q1 2026 at Integra Lifesciences Holdings, down from $23.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $23.0 million in Q4 2025 to a low of -$19.2 million in Q1 2024.
• A 5-year average of $116352.9 and a median of -$4.8 million in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses jumped 1944.11% in 2022 and sank 380.33% in 2024, its largest moves.
• Integra Lifesciences Holdings' Change in Accured Expenses stood at $18.1 million in 2022, then slumped by 89.46% to $1.9 million in 2023, then sank by 380.33% to -$5.4 million in 2024, then soared by 529.48% to $23.0 million in 2025, then slumped by 183.34% to -$19.2 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$19.2 million, $23.0 million, and $5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison